Incontinence during treatment with gabapentin.
Gil-Nagel
A
A
Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA.
Gapany
S
S
Blesi
K
K
Villanueva
N
N
Bergen
D
D
D000085:Acetates / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003509:Cyclohexanecarboxylic Acids; D004827:Epilepsy / Q000188:drug therapy; D005242:Fecal Incontinence / Q000139:chemically induced*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008297:Male; D014549:Urinary Incontinence / Q000139:chemically induced*; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin